Dr. Mita is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
7703 Floyd Curl Dr
# MC7977
San Antonio, TX 78229Phone+1 210-257-1400Fax+1 210-257-1428
Summary
- Alain C. Mita, M.D., M.S.c., is an oncologist at Hoag Family Cancer Institute specializing in the treatment of lung, thyroid and head & neck cancers, as well as in the development of new therapies for cancer.
Before joining Hoag, Dr. Mita served as Co-Director of Experimental Therapeutics at the Samuel Oschin Comprehensive Cancer Institute as well as
Associate Professor of Medicine at Cedars-Sinai Medical Center. He was also Professor of Medicine at University of California, Los Angeles. An accomplished researcher, Dr. Mita has served as the principal investigator or co-principal investigator on numerous phase I-II clinical trials testing the effects
of new drug therapies for cancer treatment.
Dr. Mita earned his medical degree at the University of Medicine and Pharmacy “Carol Davila” in Bucharest, Romania, as well as a Master of Science degree in Cellular Regulation and Pathology of Regulations, Hematology and Immunology.
Dr. Mita completed his fellowship in Medical Oncology at the University of Texas Health Science Center San Antonio, Texas. He also completed an Advanced Oncology Drug Development Fellowship
Program at the Institute for Drug Development at the Cancer Therapy and Research Center and University of Texas Health Science Center.
Dr. Mita has presented and taught multiple clinical lectures throughout his career and contributed to more than 250 peer-reviewed research papers and clinical abstracts on the efficacy of oncology drug therapies.
Education & Training
- University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 2002 - 2003
- Carol Davila University of Medicine and PharmacyClass of 1992
Certifications & Licensure
- CA State Medical License 2013 - 2025
- AL State Medical License 2005 - 2024
- TX State Medical License 2006 - 2024
Clinical Trials
- Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Start of enrollment: 2005 Jan 01
- Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors Start of enrollment: 2005 Feb 01
- Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia Start of enrollment: 2008 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 37 citationsPhase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced ...Monica M. Mita, Alain C. Mita, Jennifer L. Moseley, Jennifer Poon, Karen Small
British Journal of Cancer. 2017-08-31 - 27 citationsSafety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid TumorsLee S. Rosen, Igor Puzanov, Gregory Friberg, Emily Chan, Yuying C. Hwang
Clinical Cancer Research. 2012-06-15 - 23 citationsRandomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.Lee M. Krug, Antoinette J. Wozniak, Hedy L. Kindler, Ronald Feld, Marianna Koczywas
Lung Cancer. 2014-09-01
Authored Content
- Human Papillomavirus–Associated Oropharyngeal Cancer Among Patients Aged 70 and Older: Dramatically Increased Prevalence and Clinical ImplicationsOctober 2018
Press Mentions
- Hoag Taps 2 Oncology Leaders from Cedars-SinaiApril 29th, 2024
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: